CV Sciences (OTCMKTS:CVSI) vs. Sigyn Therapeutics (OTCMKTS:SIGY) Head to Head Contrast

Risk and Volatility

Sigyn Therapeutics has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Comparatively, CV Sciences has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.

Insider & Institutional Ownership

10.0% of Sigyn Therapeutics shares are owned by institutional investors. 78.5% of Sigyn Therapeutics shares are owned by company insiders. Comparatively, 6.7% of CV Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sigyn Therapeutics and CV Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sigyn Therapeutics	N/A	N/A	N/A
CV Sciences	-11.15%	-94.61%	-20.85%

Earnings and Valuation

This table compares Sigyn Therapeutics and CV Sciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sigyn Therapeutics	N/A	N/A	-$3.34 million	($2.10)	-0.01
CV Sciences	$13.79 million	0.34	-$960,000.00	N/A	N/A

CV Sciences has higher revenue and earnings than Sigyn Therapeutics.

Summary

Sigyn Therapeutics beats CV Sciences on 5 of the 8 factors compared between the two stocks.

About Sigyn Therapeutics

Sigyn Therapeutics, Inc., a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats. The company is also involved in evaluating the Sigyn Therapy to address various therapeutic targets, including endotoxin; peptidoglycan and lipoteichoic acid; viral pathogens; hepatic toxins; and tumor necrosis factor alpha, interleukin-1 beta, and interleukin 6, which are pro-inflammatory cytokines. In addition, it develops ChemoPrep to enhance the tumor site delivery of chemotherapy; ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis; and ImmunePrep to enhance the potential efficacy of immunotherapeutic antibodies. Sigyn Therapeutics, Inc. was founded in 2019 and is headquartered in San Diego, California.

About CV Sciences

CV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.